TCS 359

TCS 359 is an inhibitor of FLT3 used in studies of MAPK / ERK Signaling and JAK-STAT Signaling. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation in angiogenesis, cancer, and cell signaling models.

By inhibiting FLT3, TCS 359 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving FLT3
• Pathway perturbation studies connected to MAPK / ERK Signaling and JAK-STAT Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, TCS 359 is appropriate when a defined chemical perturbant is needed to connect FLT3 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.